130 related articles for article (PubMed ID: 21245486)
1. NK314 potentiates antitumor activity with adult T-cell leukemia-lymphoma cells by inhibition of dual targets on topoisomerase II{alpha} and DNA-dependent protein kinase.
Hisatomi T; Sueoka-Aragane N; Sato A; Tomimasu R; Ide M; Kurimasa A; Okamoto K; Kimura S; Sueoka E
Blood; 2011 Mar; 117(13):3575-84. PubMed ID: 21245486
[TBL] [Abstract][Full Text] [Related]
2. NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform.
Toyoda E; Kagaya S; Cowell IG; Kurosawa A; Kamoshita K; Nishikawa K; Iiizumi S; Koyama H; Austin CA; Adachi N
J Biol Chem; 2008 Aug; 283(35):23711-20. PubMed ID: 18596031
[TBL] [Abstract][Full Text] [Related]
3. NK314, a novel topoisomerase II inhibitor, induces rapid DNA double-strand breaks and exhibits superior antitumor effects against tumors resistant to other topoisomerase II inhibitors.
Onda T; Toyoda E; Miyazaki O; Seno C; Kagaya S; Okamoto K; Nishikawa K
Cancer Lett; 2008 Jan; 259(1):99-110. PubMed ID: 17998154
[TBL] [Abstract][Full Text] [Related]
4. DNA-dependent protein kinase and ataxia telangiectasia mutated (ATM) promote cell survival in response to NK314, a topoisomerase IIα inhibitor.
Guo L; Liu X; Jiang Y; Nishikawa K; Plunkett W
Mol Pharmacol; 2011 Aug; 80(2):321-7. PubMed ID: 21546556
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of DNA-PK potentiates the synergistic effect of NK314 and etoposide combination on human glioblastoma cells.
Kopa P; Macieja A; Gulbas I; Pastwa E; Poplawski T
Mol Biol Rep; 2020 Jan; 47(1):67-76. PubMed ID: 31583565
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of topoisomerase IIalpha and G2 cell cycle arrest by NK314, a novel benzo[c]phenanthridine currently in clinical trials.
Guo L; Liu X; Nishikawa K; Plunkett W
Mol Cancer Ther; 2007 May; 6(5):1501-8. PubMed ID: 17513599
[TBL] [Abstract][Full Text] [Related]
7. Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair.
Toulany M; Kehlbach R; Florczak U; Sak A; Wang S; Chen J; Lobrich M; Rodemann HP
Mol Cancer Ther; 2008 Jul; 7(7):1772-81. PubMed ID: 18644989
[TBL] [Abstract][Full Text] [Related]
8. DNA-PKcs deficiency inhibits glioblastoma cell-derived angiogenesis after ionizing radiation.
Liu Y; Zhang L; Liu Y; Sun C; Zhang H; Miao G; Di CX; Zhou X; Zhou R; Wang Z
J Cell Physiol; 2015 May; 230(5):1094-103. PubMed ID: 25294801
[TBL] [Abstract][Full Text] [Related]
9. DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemia.
Haines E; Nishida Y; Carr MI; Montoya RH; Ostermann LB; Zhang W; Zenke FT; Blaukat A; Andreeff M; Vassilev LT
Sci Rep; 2021 Jun; 11(1):12148. PubMed ID: 34108527
[TBL] [Abstract][Full Text] [Related]
10. The polyphenolic ellagitannin vescalagin acts as a preferential catalytic inhibitor of the α isoform of human DNA topoisomerase II.
Auzanneau C; Montaudon D; Jacquet R; Puyo S; Pouységu L; Deffieux D; Elkaoukabi-Chaibi A; De Giorgi F; Ichas F; Quideau S; Pourquier P
Mol Pharmacol; 2012 Jul; 82(1):134-41. PubMed ID: 22528119
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the DNA-dependent protein kinase catalytic subunit radiosensitizes malignant glioma cells by inducing autophagy.
Daido S; Yamamoto A; Fujiwara K; Sawaya R; Kondo S; Kondo Y
Cancer Res; 2005 May; 65(10):4368-75. PubMed ID: 15899829
[TBL] [Abstract][Full Text] [Related]
12. The dual topoisomerase inhibitor A35 preferentially and specially targets topoisomerase 2α by enhancing pre-strand and post-strand cleavage and inhibiting DNA religation.
Zhao W; Jiang G; Bi C; Li Y; Liu J; Ye C; He H; Li L; Song D; Shao R
Oncotarget; 2015 Nov; 6(35):37871-94. PubMed ID: 26462155
[TBL] [Abstract][Full Text] [Related]
13. Echinoside A, a new marine-derived anticancer saponin, targets topoisomerase2alpha by unique interference with its DNA binding and catalytic cycle.
Li M; Miao ZH; Chen Z; Chen Q; Gui M; Lin LP; Sun P; Yi YH; Ding J
Ann Oncol; 2010 Mar; 21(3):597-607. PubMed ID: 19773249
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the effect of three different topoisomerase II inhibitors combined with cisplatin in human glioblastoma cells sensitized with double strand break repair inhibitors.
Macieja A; Kopa P; Galita G; Pastwa E; Majsterek I; Poplawski T
Mol Biol Rep; 2019 Aug; 46(4):3625-3636. PubMed ID: 31020489
[TBL] [Abstract][Full Text] [Related]
15. Inhibiting DNA-PKcs in a non-homologous end-joining pathway in response to DNA double-strand breaks.
Dong J; Zhang T; Ren Y; Wang Z; Ling CC; He F; Li GC; Wang C; Wen B
Oncotarget; 2017 Apr; 8(14):22662-22673. PubMed ID: 28186989
[TBL] [Abstract][Full Text] [Related]
16. Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K.
Munck JM; Batey MA; Zhao Y; Jenkins H; Richardson CJ; Cano C; Tavecchio M; Barbeau J; Bardos J; Cornell L; Griffin RJ; Menear K; Slade A; Thommes P; Martin NM; Newell DR; Smith GC; Curtin NJ
Mol Cancer Ther; 2012 Aug; 11(8):1789-98. PubMed ID: 22576130
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of topoisomerase IIα sensitizes FaDu cells to ionizing radiation by diminishing DNA repair.
Saleh EM
Tumour Biol; 2015 Nov; 36(11):8985-92. PubMed ID: 26081617
[TBL] [Abstract][Full Text] [Related]
18. Suppression of DNA-dependent protein kinase sensitize cells to radiation without affecting DSB repair.
Gustafsson AS; Abramenkovs A; Stenerlöw B
Mutat Res; 2014 Nov; 769():1-10. PubMed ID: 25771720
[TBL] [Abstract][Full Text] [Related]
19. A cysteine-reactive alkyl hydroquinone modifies topoisomerase IIα, enhances DNA breakage, and induces apoptosis in cancer cells.
Lin TY; Huang CP; Au LC; Chang YW; Hu CY; Lin SB
Chem Res Toxicol; 2012 Nov; 25(11):2340-51. PubMed ID: 23088786
[TBL] [Abstract][Full Text] [Related]
20. Ethonafide-induced cytotoxicity is mediated by topoisomerase II inhibition in prostate cancer cells.
Pourpak A; Landowski TH; Dorr RT
J Pharmacol Exp Ther; 2007 Jun; 321(3):1109-17. PubMed ID: 17351106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
